AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected ...

A Capital Region manufacturer expects to continue growing its revenue over the next year, though its bottom line could take a ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

Fintel reports that on July 16, 2025, Lake Street initiated coverage of AngioDynamics (NasdaqGS:ANGO) with a Buy ...

Gain insights into AngioDynamics' Q4 2025 earnings, highlighting 12% revenue growth, international expansion, Med Tech advances, and a strong FY26 outlook.

AngioDynamics, Inc. ( NASDAQ: ANGO) Q4 2025 Earnings Conference Call July 15, 2025 8:00 AM ET James C. Clemmer - CEO, President & Director Stephen A. Trowbridge - Executive VP & CFO ...

AngioDynamics (ANGO) delivered earnings and revenue surprises of +76.92% and +7.52%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics expects full-year results to range from a loss of 35 cents per share to a loss of 25 cents per share, with revenue in the range of $305 million to $310 million. AngioDynamics shares have ...

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

Piccolo Medical, Inc. (Piccolo), a leading innovator in vascular access technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next ...

Authorities at Tehran's Evin Prison were still attending to the dead and wounded on the evening of June 23 when one of the highest-profile inmates held there, Swedish-Iranian scientist Ahmadreza ...